

---

# S&P TEST

SWOT & PESTLE.com

---

## EMERGENT BIOSOLUTIONS INC. SWOT & PESTLE ANALYSIS

© Barakaat Consulting - An Ezzy IT Consulting Business

This is a licensed product and is not to be photocopied or distributed. All rights reserved. Unauthorized reproduction is strictly prohibited. Research is based on best available materials and resources. To purchase reprints of this document, please email [support@swotandpestle.com](mailto:support@swotandpestle.com).

**Company Name :** Emergent BioSolutions Inc.

**Company Sector :** Biotechnology

**Operating Geography :** United States, North America, Global

**About the Company :** Emergent BioSolutions Inc., headquartered in Gaithersburg, Maryland, is an American multinational specialty biopharmaceutical company. It creates vaccines and antibody therapeutics to treat infectious diseases and opioid overdoses, as well as biodefense medical devices. Faud El-Hibri created Emergent BioSolutions on September 5, 1998, under the name BioPort, and renamed it Emergent BioSolutions in 2004. The company has four main units: vaccines, which manufactures specialty vaccines for public health threats; devices, which include nasal sprays, skin lotions, and injections; therapeutics, which involves antibiotic treatments; and contract development and production, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the US government. The majority of revenue comes from vaccination, device, and medicinal product purchases by the US government. On June 11, 2021 the company announced that two batches of COVID-19 vaccine manufactured at its Baltimore Bayview facility had been determined to be suitable for use by the US Food and Drug Administration (FDA) and had been authorised as part of Johnson & Johnson's Emergency Use Authorization programme (EUA).

Emergent BioSolutions's unique selling point or USP lies in its wide product and service portfolio, which allows it to remain confident in executing its plan, meeting its commitments to partners and consumers, and producing value for its shareholders. Emergent BioSolutions's mission statement reads, "Emergent's mission to protect and enhance life applies not only to the products and services that we deliver, but also to how we serve the communities in which we live and work. Our eGive program enables every employee to bring their skills, their passion and their energy to building healthier and safer communities".

**Revenue :**

US\$ 1,555 million - FY ending 31st December 2020 (y-o-y growth 40.6%)

US\$ 1,106 million - FY ending 31st December 2019

## SWOT Analysis :

The SWOT Analysis for Emergent BioSolutions Inc. is given below:

Strengths	Weaknesses
<ul style="list-style-type: none"> <li>1.Largest supplier of BioThrax, the only FDA approved anthrax vaccine</li> <li>2.Diversified portfolio of products + pipeline plus CDMO services</li> <li>3.Strong public private partnerships</li> <li>4.Readiness to battle the biochemical threats</li> <li>5.Established manufacturing expertise through own and contractual locations</li> </ul>	<ul style="list-style-type: none"> <li>1.Ongoing investigations regarding government vaccine contracts</li> <li>2.Substantial portion of revenues dependent on USG procurement</li> <li>3. History of manufacturing failures</li> <li>4 Top management not adhering to stock market regulations</li> <li>5. Poorly trained employees, incapable of expanding production</li> </ul>
Opportunities	Threats
<ul style="list-style-type: none"> <li>1.Increasing public health threats to drive growth</li> <li>2.Worsened opioid crisis, boosts demand for NARCAN</li> <li>3.Product candidates to cure critical Covid-19 patients</li> </ul>	<ul style="list-style-type: none"> <li>1.Poor image will cause loss of existing contracts</li> <li>2.Disruption of travel related vaccines due to Covid-19</li> <li>3.Delayed product launches due to cancellations of clinical trials in Covid</li> </ul>

## PESTLE Analysis :

The PESTLE Analysis for Emergent BioSolutions Inc. is given below:

Political	Economical
1.Government funding diverted from flagship products due to Covid 2.Joe Biden's strengthened implementation of Affordable Care Act affects pricing	1.Discontinuation of LIBOR complicates financing 2.High flow of investments into health and biotechnology
Social	Technological
1.Vaccine makers are venerated as they give hope	1.Mixed vaccine can fight multiple strains of a virus 2.mRNA technology is the future of biopharmaceuticals
Legal	Environmental
1.Pandemic Act (PAHPA) of 2019 authorizes better funding for product development 2.FDA approvals take long durations and substantial financial resources	1.Experimental use of animals must follow stringent norms

Please note that our free summary reports contain the SWOT and PESTLE table contents only. The complete report for **Emergent BioSolutions Inc.** SWOT & PESTLE Analysis is a paid report at **27 U.S.D.**



\* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."



# S&P

SWOT & PESTLE.com

SWOT & PESTLE.com is a leading strategy research portal covering detailed Strengths, Weaknesses, Opportunities, Threats (SWOT) and Political, Economic, Social, Technological, Legal and Environmental (PESTLE) analysis of leading industry sectors and organizations across the globe. Our full and comprehensive collection on SWOT and PESTLE has been written by our team of professional analysts consisting of MBA's, CFA's and industry experts. Our analysis has helped businesses, researchers and scholars with valuable insights to make strategic decisions and take their research forward.

We at SWOT & PESTLE.com aim to aid the understanding of the multifaceted business world by presenting a list of diverse companies from across the globe. Business organizations today cannot function in ways that ignore the surroundings that they are set in. SWOT & PESTLE.com makes a keen observation into this aspect and accounts for factors affecting such businesses.

# Copyright Notice

The information provided in the SWOT and PESTLE research reports on [www.swotandpestle.com](http://www.swotandpestle.com) are from publicly available documents and sources which are deemed reliable. Further the reports contain analysis and views from the SWOT & PESTLE.com research and analyst team which consists of qualified experts. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible or legal liable for omissions or errors in our reports or on any of our pages.

(C)2024 Barakaat Consulting. All rights reserved. This report may not be reproduced, copied or redistributed, in whole or in part, in any form or by any means, without the express written consent of Barakaat Consulting. Also, Barakaat Consulting is the sole copyright owner of this report, and any use of this report by any third party is strictly prohibited without a license expressly granted by Barakaat Consulting. Neither all nor any part of the contents of this report, or any opinions expressed herein, can be used in advertising, press releases, or promotional materials without prior written approval from Barakaat Consulting. Any violation of Barakaat Consultings rights in this report will be executed to the fullest extent of the law, including the pursuit of monetary damages and injunctive relief in the event of any breach of the foregoing restrictions.

Client Support:  
**[support@swotandpestle.com](mailto:support@swotandpestle.com)**